Topic

Publication type

Reference to publication

Risk vs. benefit: >100:1

Uncirc’d affected: 1 in 3

Risk-benefit analysis

Morris et al. (2006) [18]

Risk vs. benefit: >100:1

Uncirc’d affected: 1 in 3

Risk-benefit analysis

Morris (2007) [72]

Risk vs. benefit: >100:1

Uncirc’d affected: 1 in 2

Risk-benefit analysis

Morris et al. (2012) [73]

Risk vs. benefit: >100:1

Uncirc’d affected: 1 in 2

Risk-benefit analysis

Morris et al. (2014) [96]

Risk vs. benefit: >100:1

Uncirc’d affected: 1 in 1.5

Risk-benefit analysis

Morris et al. (2016) [52]

Risk vs. benefit: ~200:1

Uncirc’d affected: 1 in 1.3

Risk-benefit analysis

Morris et al. (2017) [74]

MC and lower oncogenic HPV

OR 0.52 (95% CI 0.33 - 0.82)

Meta-analysis

Morris et al. (2011) [75]

Phimosis and penile cancer risk

OR 12.1 (95% CI 5.57 - 26.2)

Meta-analysis

Morris et al. (2011) [75]

Balanitis and penile cancer risk

OR 3.82 (95% CI 1.61 - 9.06)

Meta-analysis

Morris et al. (2011) [75]

Smegma and penile cancer risk

OR 3.04 (95% CI 1.29 - 7.16)

Meta-analysis

Morris et al. (2011) [75]

MC and reduction in penile

inflammatory skin conditions

OR 0.32 (95% CI 0.20 - 0.52)

Meta-analysis

Morris et al. (2012) [76]

Morris & Krieger (2017) [98]

MC and meatal stenosis risk

Risk 0.66% (95% CI 0.43 - 0.91)

Meta-analysis

Morris & Krieger (2017) [99]

MC and lower lifetime UTI risk

OR 0.27 (95% CI 0.085 - 0.87)

Systematic review and

meta-analysis

Morris & Wiswell (2013) [77]

MC and sexual function,

sensitivity and sensation

Systematic review

Morris & Krieger (2013) [37]

Country-specific and global

Prevalence of MC

Systematic review

Morris et al. (2016) [79] [80]

MC, benefits and risks

Systematic review

Morris et al. (2017) [74]

MC and penile inflammatory skin conditions

Systematic review

Morris & Krieger (2017) [78]

World first patent for use of PCR for viral (HPV) testing

Patents: US, Australia,

Europe, Japan

Morris & Nightingale (1987) [100]